Format

Send to

Choose Destination
CNS Neurosci Ther. 2014 Jul;20(7):591-602. doi: 10.1111/cns.12264. Epub 2014 Apr 7.

The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.

Author information

1
Department of Physiology and Biochemistry, University of Malta, Msida 2080, Malta.

Abstract

Parkinson's disease (PD) is an incurable neurodegenerative disorder leading to progressive motor impairment and for which there is no cure. From the first postmortem account describing a lack of mitochondrial complex I in the substantia nigra of PD sufferers, the direct association between mitochondrial dysfunction and death of dopaminergic neurons has ever since been consistently corroborated. In this review, we outline common pathways shared by both sporadic and familial PD that remarkably and consistently converge at the level of mitochondrial integrity. Furthermore, such knowledge has incontrovertibly established mitochondria as a valid therapeutic target in neurodegeneration. We discuss several mitochondria-directed therapies that promote the preservation, rescue, or restoration of dopaminergic neurons and which have been identified in the laboratory and in preclinical studies. Some of these have progressed to clinical trials, albeit the identification of an unequivocal disease-modifying neurotherapeutic is still elusive. The challenge is therefore to improve further, not least by more research on the molecular mechanisms and pathophysiological consequences of mitochondrial dysfunction in PD.

KEYWORDS:

Mitochondria; Neuroprotection; Oxidative stress; Parkinson's disease; Therapeutics

PMID:
24703487
DOI:
10.1111/cns.12264
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center